Although PEG remains the gold standard for the steric protection

Although PEG remains the gold standard for the steric protection of liposomes [50], it creates an impermeable layer over the liposome surface [51] which could decrease availability of blood asparagines to encapsulated ASNase II. However, research in nanomedicine offers a unique platform for a variety of manipulations that can this website Further enhance the value of the https://www.selleckchem.com/products/Temsirolimus.html delivered drugs. Conclusions It could be assumed by this study that, when the CSNPs are loaded with hydrophilic macromolecules or drugs, the interactions between them and the gel network can effectively make particles much more stable. The preparation of ASNase II-loaded CSNPs was based on an ionotropic interaction between the positively

charged CS and the negatively charged ASNase II and TPP. The negatively click here charged ASNase II was able to link CS chains electrostatically at pH ~ 5.7 before the addition of the polyanion. Such ASNase II behavior was previously observed in DEAE-Sepharose

column by positively charged amine groups of DEAE. ASNase II-CS interactions would be strengthened by adding a polyanion and rising pH. So, it could be assumed that CS networks were formed through two cross-linkers of TPP and ASNase II, and the drug itself helped particle formation that is of great interest in pharmaceutical productions. The pH and thermal stability, release, and half-life of ASNase II were evaluated. Compared to the free ASNase II, the immobilized enzyme was more resistant to alkaline pH (8.5 to 9.5) and to high temperatures. ASNase II release could be influenced by pH and the ionic strength of the medium. The immobilized enzyme had an increased half activity time of about 23 days in the low ionic strength solution and about

6.4 days in the high ionic strength solution. This in vitro study would provide an impetus for the future in vivo investigations. Further studies will be needed to find a suitable particle size and charge, biological responses, and administration route to apply in drug delivery and in vivo use. Acknowledgements We would like to thank the members of the Biotechnology Department of Razi Vaccine and Serum Research Institute for their help. This work was supported partly by Iran Nanotechnology Initiative Council and Hamadan University of Medical Sciences. References 1. Narta UK, Paclitaxel supplier Kanwar SS, Azmi W: Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol 2007, 61:208–221. 10.1016/j.critrevonc.2006.07.009CrossRef 2. Pasut G, Sergi M, Veronese FM: Anti-cancer PEG-enzymes: 30 years old, but still a current approach. Adv Drug Deliv Rev 2008, 60:69–78. 10.1016/j.addr.2007.04.018CrossRef 3. Wolf M, Wirth M, Pittner F, Gabor F: Stabilisation and determination of the biological activity of L-asparaginase in poly(D, L-lactide-co-glycolide) nanospheres. Int J Pharm 2003, 256:141–152. 10.

Comments are closed.